In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $8.70.
According to TipRanks, Stranahan is a 4-star analyst with an average return of 9.1% and a 58.82% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Recursion Pharmaceuticals, and Novavax.
Recursion Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $16.83.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $16.75 and a one-year low of $4.54. Currently, Recursion Pharmaceuticals has an average volume of 6.2M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Read More on RXRX:
- Recursion to Participate in Upcoming Investor Conferences
- Cathie Wood’s ARK Investment bought 132.2K shares of Recursion Pharmaceuticals
- Cathie Wood’s ARK Investment bought 357.3K shares of Recursion Pharmaceuticals
- Recursion screens Enamine REAl Space library using MatchMaker technology
- Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
